LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Legal & Regulatory and Reimbursement/FDA Clears Zimmer Biomet’s ROSA® Robotic Hip System
Legal & Regulatory and Reimbursement

FDA Clears Zimmer Biomet’s ROSA® Robotic Hip System

August 27, 2021 1 min read Premium comments

Advertisement

#fda510kclearance#hipreplacement#zimmerbiometSecondary

On August 18, 2021, Zimmer Biomet Holdings, Inc., announced FDA 510(k) clearance for its ROSA® Hip System for robotically-assisted direct anterior total hip replacement.

Technically called ONE Planner Hip in FDA clearance documents, the system is a medical imaging management and processing system intended for use as preoperative surgical planning software “to aid orthopedic surgeons in component selection, sizing and placement for primary total hip arthroplasty.”

System Functions

According to the FDA clearance documents, the fluoroscopic-based system is an interactive software application which “enables 2D sizing and positioning of implants in the patient’s anatomy, calculates biomechanical measurements and performs functional analysis based on the patient’s pelvic kinematics.”

The biomechanical measurements relate to leg length and femoral offset. The functional analysis includes determination of pelvic parameters (e.g., pelvic tilt), and cup orientation calculations. The software application consists of an automated templating system and a web-based templating user interface.

The intra-operative data collected by the system is combined with pre- and post-operative data collected by mymobility® with Apple Watch® and consolidated and analyzed by the company’s OrthoIntel Orthopedic Intelligence Platform.

The system can be used with the following implant systems:

  • G7 Acetabular Systems
  • Taperloc Complete Stems
  • Echo Bi-Metric Stems
  • Avenir Complete
  • Avenir Muller and Cemented Hip Stems

The company said the system features a “simplified set-up that doesn’t require pins or reference arrays, and it can be used with X-ray images instead of CT scans.” The company also said the system is the latest addition to ZBEdge, Zimmer Biomet’s suite of digital robotic technologies. Other systems include the ROSA Knee System for total knee arthroplasty, ROSA Partial Knee System for partial knee arthroplasty and ROSA ONE for neurosurgical and spine procedures.

Advertisement

This is the fourth robotic system introduced by Zimmer since it acquired Montreal-based ORTHOsoft in 2007 for $50 million (Canadian dollars). ORTHOsoft was founded in 1995 to develop medical software, instruments, and computerized systems.

Ivan Tornos, the company’s Chief Operating Officer, said, “as an integrated component of our ZBEdge Connected Intelligence Suite, ROSA Hip advances our vision to translate pre-, intra-and post-operative data into actionable clinical insights to inform personalized care decisions.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy